In addition to its role in neurodevelopmental disorders (Houge et al., 2015; Loveday et al., 2015; Shang et al., 2016; Reynhout et al., 2019; Biswas et al., 2020; Lenaerts et al., 2021), PP2A is mostly known as a tumour suppressor and its inhibition caused by mutation, biochemical downregulation or drug binding is implicated in many cancers (Eichhorn et al., 2009; Ruediger et al., 2011; Ruvolo, 2016; O’Connor et al., 2020). Here, PTPA is linked to cancer.